ochsenbein lab

Group Ochsenbein

Publications

Original Articles

2023

• Näf, P., Radpour, R., Ruckstuhl, C., Bodmer, N., Baerlocher, G.M., Döhner, H., Döhner, K., Riether C., and Ochsenbein, A.F.. 2023. IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways.
  Science Signaling.
  PubMED

2022

• Bührer, E.D., Amrein, M.A., Forster, S., Isringhausen, S., Schurch, C.M., Bhate, S.S., Brodie, T., Zindel, J., Stroka, D., Al-Sayed, M., Nombela-Arrieta, C., Radpour, R., Riether C., and Ochsenbein, A.F.. 2022. Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.
  Leukemia.
  PubMED
• Deng, H., Gao, Y., Trappetti, V., Hertig, D., Karatkevich, D., Losmanova, T., Urzi, C., Ge, H., Geest, G.A., Bruggmann, R., Djonov, V., Nuoffer, J.M., Vermathen,P., Zamboni, N., Riether, C., Ochsenbein, A.F., Peng, R.W., Kocher, G.J., Schmid, R.A., Dorn. P., Marti. T.M. 2022. Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage.
  Cellular and Molecular Life Sciences.
  PubMED

2021

• Hinterbrandner, M., Rubino, V., Stoll, C., Forster, S., Schnüriger, N., Radpour R., Baerlocher, G.M., Ochsenbein, A.F., and Riether, C. 2021. Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.
  JCI Insight.
  PubMED
• Radpour R., Stucki, M., Riether, C. and Ochsenbein, A.F. 2021. Epigenetic silencing of immune-checkpoint receptors in bone marrow- infiltrating T cells in acute myeloid leukemia.
  Frontiers in Oncology
  PubMED
• Höpner, S., Raykova, A., Radpour R., Amrein, M., Koller, D., Baerlocher, G.M., Riether, C. and Ochsenbein, A.F.. 2021. LIGHT/LTBR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells.
  Nature Communications
  PubMED
• Riether C., Radpour R., Kallen N.M., Bürgin D. T., Bachmann, C., Schürch, C.M., Lüthi, U., Armabasic M., Hoppe, S., Albers, C.E., Baerlocher, G.M. and Ochsenbein, A.F. 2021. Metoclopramide treatment blocks CD93-signaling mediated self-renewal of chronic myeloid leukemia stem cells.
  Cell Reports
  PubMED

2020

• Amrein M.A., Bührer E.D., Amrein M.L., Li Q., Rothschild S., Riether C., Jaggi R., Savic-Prince, Bubendorf L., Gautschi O.and Ochsenbein, A.F. 2020. Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study.
  Cancer Immunol Immunother
  PubMED
• Riether C., Pabst T., Höpner S., Bacher U., Hinterbrandner M., Banz Y., Müller R., Manz M. G., Gharib W. H., Francisco D., Bruggmann R., van Rompaey L., Moshir M., Delahaye T., Gandini D., Erzeel E., Hultberg A., Fung S., de Haard H., Leupin N., and Ochsenbein, A.F. 2020. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
  Nature Medicine.
  PubMED
• Riether C. and Ochsenbein, A.F. 2020. Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.
  Cancer Cell.
  PubMED
• Jaeger-Ruckstuhl C.A., Hinterbrandner M., Höpner S., Correnti C.E., Lüthi U., Friedli O., Freigang S., Al Sayed M.F., Bührer E.D., Amrein M.A., Schürch C.M., Radpour R., Riether C. and Ochsenbein, A.F. 2020. TNIK signaling imprints CD8+ T cell memory formation early after priming.
  Nature Communications.
  PubMED

2019

• Radpour, R., Riether, C., Simillion, C., Höpner, S., Bruggmann, R., and Ochsenbein, A.F. 2019. CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.
  Leukemia.
  PubMED
• Salomé, B., Gomez-Cadena, A., Loyon, R., Suffiotti, M., Salvestrini, V., Wyss, T., Vanoni, G., Ruan, D.F., Rossi, M., Tozzo, A., Tentorio, P., Bruni, E., Riether, C., Jacobsen, E.M., Jandus, P., Conrad, C., Hoenig, M., Schulz, A., Michaud, K., Della Porta, M.G., Salvatore, S., Ho, P.C., Gfeller, D., Ochsenbein, A.F., Mavilio, D., Curti, A., Marcenaro, E., Steinle, A., Horowitz, A., Romero, P., Trabanelli, S., Jandus, C. 2019. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
  Blood Adv.
  PubMED

2018

• Liang, S., Bührer, E.D., Berezowska, S., Thomas M.M., Xu, D., Froment, L., Yang, H., Hall, S.R.R, Vassella, E., Yang, Z., Kocher, G.J., Amrein, M.A., Riether, C., Ochsenbein, A.F., Schmid, R.A. and Peng, R. 2018. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
  Oncogene.
  PubMED
• AL-Sayed, M., Amrein, M.A., Bührer, E.D., Huguenin, A.L., Radpour, R., Riether, C. and Ochsenbein, A.F. 2018. T-cell-secreted TNF-alpha induces emergency myelopoiesis and myeloid-derived suppressor cell-differentiation in cancer.
  Cancer Research.
  PubMED
• Tièche1, C.C., Bührer, E.D., Gao1, Y., Hobi, N., Berezowska, S.A., Wyler, K., Froment, L., Weis, S., Peng, R., Bruggmann, R., Schär, P., Amrein, M.A.,, Hall, S.R.R., Dorn1, P., Kocher1, G., Riether, C., Ochsenbein, A., Schmid1, R.A., Marti1, T.M. 2018. Tumor initiation capacity and therapy resistance are differential features of EMT-related subpopulations in the NSCLC cell line A549.
  Neoplasia.
  PubMED

2017

• Hilmenyuk, T., Ruckstuhl, C.A., Hayoz, M., Berchtold, C., Nuoffer, J.M., Solanki,S., Keun, H.C., Beavis, P.A. , Riether, C., and Ochsenbein, A.F. 2017. T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.
  Oncoimmunology.
  PubMED
• Riether, C., Schurch, C.M., Bührer, E.D., Hinterbradner, M., Huguenin, A., Hoepner, S., Zlobec, I., Pabst, T., Radpour, R., and Ochsenbein, A.F.. 2017. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.
  The Journal of Experimental Medicne 214(2):359-380.
  PubMED
• Al Sayed, M.F., Ruckstuhl, C.A., Hilmenyuk, T., Claus, C., Bourquin, J.P., Bornhauser, B.C., Radpour, R., Riether, C., and Ochsenbein, A.F.. 2017. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
  Blood 130:297-309.
  PubMED

2015

• Riether C., Schürch C., Flury C., Hinterbrandner M., Drück L., Huguenin A., Baerlocher G.M., Radpour R., Ochsenbein A.F. Tyrosin kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling.
  Science Translational Medicine 2015, 10.1126/scitranslmed.aab1740
  PubMED

2014

• Schürch C., Riether C., Ochsenbein A.F. Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells.
  Cell Stem Cell 2014, 10.1016/j.stem-2014.01.002
  PubMED

2013

• Schürch C., Riether C., Amrein M.A., Ochsenbein A.F. Cytotoxic T cells increase the proliferation of chronic myeloid leukemia stem cells by secreting interferon-g.
  Journal of Experimental Medicine 2013, 210:605-621.
  PubMED

2012

• Fahrner R., Ochsenbein A., Schmid R.A., Carboni G.L. Long term survival after trimodal therapy in malignant pleural mesothelioma.
  Swiss Medical Weekly 2012, 142:w13686.
  PubMED
• Zappa F., Droege C., Betticher D., von Moos R., Bubendorf L., Ochsenbein A., Gautschi O., Oppliger Leibundgut E., Froesch P., Stahel R., Hess T., Rauch D., Schmid P., Mayer M., Crowe S., Brauchli P., Ribi K., Pless M. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cencer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trail (SAKK 19/05).
  Lung Cancer 2012, 78:239-244.
  PubMED
• Schoenewolf N.L., Dummer R. Michic-Probst D., Moch H., Simcock M., Ochsenbein A., Gillessen S., Schraml P., von Moos R. Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with two State of the Art Techniques.
  Case Reports in Oncology 2012, 5:280-289.
  PubMED
• Claus, C., Riether C., Schürch, C., Matter M.S., Hilmenyuk T., Ochsenbein A.F. CD27-signaling increases the frequency of regulatory T cells and promotes tumor growth.
  Cancer Research 2012, 72:3664-3676.
  PubMED
• Schürch C., Riether C., Matter M.S., Tzankov A., Ochsenbein A.F. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.
  Journal of Clinical Investigation, 2012, 122(2):624–638.
  PubMED
• Schraml P. Von Teichman A., Mihic-Probst D., Simcock M., Ochsenbein A., Dummer R., Michelin O., Seifert B., Schläppi M., Moch H., von Moos R. Predicitive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK50/07.
  Oncology Reports 2012; 28:654-658.
  PubMED

2011

• Matter M.S., Hilmenyuk T., Claus C., Marone R., Schürch C., Tinguely M., Terracciano L., Luther S.A., Ochsenbein A.F. Destruction of Lymphoid Organ Architecture and Hepatitis caused by Cytotoxic CD4+ T Cells.
  PLoS ONE 2011, 6(9):e24772
  PubMED
• Von Moos R., Seifert B., Simrock M., Goldinger SM., Ochsenbein A.F., Michielin O., Cathomas R., Moch H., Schraml P.H., Mjhic-Probst D. Mamot C., Schönewolf N., Dummer R. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07),
  Annals of Oncology 2011, 23(2):531-536.
  PubMED
• Hofer S., Elandt K., Greil R., Hottinger AF., Huber U., Lemka D., Marosi C., Ochsenbein A.F., Pichler J., Roelcke U., Weder P., Zander T., Wick W., Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
  Acta Oncologica 2011, 50:630-635.
  PubMED
• Ochsenbein A.F., Schubert A.D., Vasella E., Mariani L. Quantitative analysis of O6-Methylguanine DNA Methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
  Journal of Neuro-Oncology 2011, 103:343-351.
  PubMED

2010

• Mumprecht S., Schürch C., Scherrer S., Claus C., Ochsenbein A.F. Chronic myelogenous leukemia maintains specific CD8+ T cells through IL-7 signalling.
  European Journal of Immunology 2010, 40:2720-3270.
  PubMED
• Stupp R., Hegi ME., Neys B., Goldbrunner R., Schlegel U., Clement P., Grabenbauer GG., Ochsenbein A.F., Schramm J., Dietrich PY., Pietsch T., Tonn JC., Pica A., Hermisson M., Krueger S., Picard M., Weller M. Phase I/II study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
  Journal of Clinical Oncology 2010, 28:2712-2718.
  PubMED
• Fatz L., Hegazy A.N., Bergthaler A., Verschoor A., Claus C., Fernandez M., Gattinoni L., Johnson S., Kreppel F., Kochanek S., van den Broek M., Radbruch A. Lévy F., Lambert P.H., Siegrist C.A., Restifo N.P., Löhning M., Ochsenbein A.F., Nabel G.J., Pinschewer D.D. Development of replication-defective lymphocytic choriomeningitis virus vectors for induction of potent CD8+ T cell immunity,
  Nature Medicine 2010, 16:339-345.
  PubMED

2009

• Mumprecht S., Schürch C., Schwaller J., Solenthaler M., Ochsenbein A.F. PD-1 signaling on chronic myeloid leukemia-specific T cells results in T cell exhaustion and disease progression,
  Blood 2009, 114:1528-1536.
  PubMED
• Pavelic V., Matter M.S., Mumprecht S., Breyer I., Ochsenbein A.F. CTL induction by cross-priming is restricted to immunodominant epitopes.
  European Journal of Immunology 2009, 39:1-13.
  PubMED
• Mumprecht S., Claus C., Schürch C., Pavelic V., Matter M.S., Ochsenbein A.F. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.
  Blood 2009, 113:4681-4689.
  PubMED

2008

• Matter M.S., Claus C., Ochsenbein A.F. CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression,
  European Journal of Immunology 2008, 38:1847-1856.
  PubMED

2007

• Matter M., Pavelic V. Pinschewer D., Eschli B., Giroglou T., von Laer D., Ochsenbein A.F. Decreased tumor surveillance after adoptive immunotherapy.
  Cancer Research 2007, 67:7467-7477.
  PubMED

2006

• Matter M., Odermatt B., Yagita H., Nuoffer J.M., Ochsenbein A.F. Elimination of chronic viral infection by blocking CD27 signalling.
  Journal of Experimental Medicine 2006, 203:2405-2408.
  PubMED
• Mumprecht S, Matter M., Pavelic V., Ochsenbein A.F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections,
  Blood 2006, 108:3406-3413.
  PubMED

2005

• Matter M., Mumprecht S., Pinschewer D.D., Pavelic V., Yagita H., Krautwald S., Borst J., Ochsenbein A.F. Virus-induced polyclonal B cell activation improves protective cytotoxic T cell memory.
  European Journal of Immunology 2005, 35:3229–3239.
  PubMED

2004

• Ochsenbein, A.F., Brown, M., Baerlocher, G., Lansdorp, P., Riddell, S.R., Greenberg, P.D. CD27 expression is required for long-term survival of effector memory CTL in HIV-infected patients.
  Journal of Experimental Medicine 2004, 200:1407-1417.
  PubMED

2002

• Ochsenbein-Imhof N., Ochsenbein A.F., Seifert B., Huch A., Huch R., Zimmermann R. Quantification of fetomaternal hemorrhage by fluorescence microscopy is equivalent to flow cytometry.
  Transfusion, 2002, 42:947-53.
  PubMED

2001

• Pinschewer D.D., Ochsenbein A.F., Fehr T., Zinkernagel R.M. Leflunomide-mediated suppression of antiviral antibody and T cell responses: differential restoration by uridine.
  Transplantation. 2001, 72:712-719.
  PubMED
• Ochsenbein A.F. Sierro S., Odermatt B. Pericin M. Karrer U., Hermans I., Hemmi S., Hengartner H., Zinkernagel R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
  Nature. 2001, 411: 712-719.
  PubMED
• Ludewig B., McCoy K., Pericin M., Ochsenbein A.F., Dumrese T., Odermatt B. Toes R.E. Melief C.J. Hengartner H., Zinkernagel R.M. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells.
  Journal of Immunology 2001, 166:3678-3687.
  PubMED

2000

• Ochsenbein A.F., Pinschewer D.D., Sierro S., Horvath E., Hengartner H., Zinkernagel R.M. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs.
  Proceedings of the National Academy of Science USA 2000, 97:13263-13268.
  PubMED
• Knobeloch, K.P., Wright M.D., Ochsenbein A.F., Liesenfeld O., Löhler J., Zinkernagel R.M., Horvak I., Orinska Z. Lack of CD37 impairs T cell dependent B cell response under suboptimal costimulatory conditions.
  Molecular Cell Biology 2000, 20:5363-5369.
  PubMED
• Ochsenbein A.F., Pinschewer D.D., Odermatt B., Ciurea A., Hengartner H., Zinkernagel R.M. Correlation of T cell independence of antibody responses with antigen dose reaching secondary lymphoid organs.
  Journal of Immunology 2000, 164:6296-6302.
  PubMED
• Pinschewer, D.D., Ochsenbein A.F., Brinkmann V., Hengartner H., Zinkernagel R.M. FTY720 Immunosuppression - impairs effector T cell peripheral homing without affecting induction, expansion and memory.
  Journal of Immunology 2000, 164:5761-5770.
  PubMED
• Ochsenbein A.F.*, Ludewig, B*., Odermatt B., Paulin D., Hengartner H., Zinkernagel R.M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells result in severe autoimmune disease.
  Journal of Experimental Medicine 2000, 191:795-804 (*equal contribution).
  PubMED
• Ciurea, A., Klenerman P., Hunziker L., Horvath E., Senn B.M., Ochsenbein A.F., Hengartner H., Zinkernagel R.M. Viral persistence in vivo through selection of neutralizing antibody-escape variants.
  Proceedings of the National Academy of Science USA 2000, 97:2749-2754.
  PubMED

1999

• Ochsenbein, A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H., Zinkernagel R.M. Control of early viral and bacterial distribution and disease by natural antibodies.
  Science 1999, 286:2156-2159.
  PubMED
• Ochsenbein, A.F., Pinschewer D.D., Odermatt B., Carroll M.C., Hengartner H., Zinkernagel R.M.. Protective T cell-independent antiviral antibody responses are dependent on complement.
  Journal of Experimental Medicine 1999, 190:1165-1174.
  PubMED
• Ciurea, A., Klenermann P., Hunziker L., Horvath E., Odermatt B., Ochsenbein A.F., Hengartner H., Zinkernagel R.M. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice.
  Proceedings of the National Academy of Science USA 1999, 96:11964-11969.
  PubMED
• Pinschewer, D.D., Ochsenbein A.F., Satterthwaite A.B., Witte O.N., Hengartner H., Zinkernagel R.M. A Btk transgene restores the antiviral TI-2 antibody response of xid mice in a dose-dependent fashion.
  European Journal of Immunology 1999, 29:2981-2987.
• Ochsenbein, A.F., Karrer U., Klenerman P., Althage A., Ciurea A., Shen H., Miller J.F., Whitton J.L., Hengartner H., Zinkernagel R.M. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria.
  Proceedings of the National Academy of Science USA 1999, 96:9293-9298.
  PubMED
• Ochsenbein, A.F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, Hengartner H., Zinkernagel R.M. Immune surveillance against a peripheral solid tumor fails because of immunological ignorance.
  Proceedings of the National Academy of Science USA 1999, 96:2233-2238.
  PubMED

1998

• Fehr, T., Naim H.Y., Bachmann M.F., Ochsenbein A.F., Spielhofer P., Bucher E., Hengartner H., Zinkernagel R.M. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nature Medicine 1998, 4:945-948.
• Lutz, C., Ledermann B., Kosco-Vilbois M., Ochsenbein A.F., Zinkernagel R.M., Köhler G., Brombacher F. IgD can largely substitute for loss of IgM function in B cells.
  Nature 1998, 393:797-801.
  PubMED

1994

• Ballmer, P.E., Ochsenbein A.F., Schutz-Hofmann S. Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease.
  Metabolism 1994, 43:697-705.
  PubMED

Reviews

2013

• Riether C., Schürch C., Ochsenbein A.F. From “magic bullets” to specific cancer immunotherapy.
  Swiss Medical Weekly 2013, 143:w13734.
  PubMED

2012

• Riether C., Schürch C., Ochsenbein A.F. Modulating CD27 signaling to treat cancer.
  Oncoimmunology 2012, 1:1604-1606.
  PubMED

2008

• Matter MS., Ochsenbein AF. Natural antibodies target virus-antibody complexes to organized lymphoid tissue.
  Autoimmunity Reviews 2008, 76:480-486.
  PubMED
• Ho C., Ochsenbein A.F. Gautschi O., Davies A.M. Early Clinical Trial Experience with Vaccine Therapies in NSCLC.
  Clinical Lung Cancer 2008, 9:S20-S27.
  PubMED

2005

• Ochsenbein A.F. Immunological ignorance of solid tumors.
  Springer Seminars in Immunopathology, 2005 27:19-35.
  PubMED

2004

• Fehr T., Ochsenbein A.F. Outcome of the antibody response: a question of antigen dose and distribution.
  Trends in Immunology 2004, 25:165-166.
  PubMED

2002

• Ochsenbein A.F. Principles of tumor immunosurveillance and their implications for immunotherapy.
  Cancer Gene Therapy 2002, 9:1043-1055.
  PubMED

2001

• Zinkernagel R.M., LaMarre A., Ciurea A., Hunziker L., Ochsenbein A.F., McCoy K.D., Fehr T., Bachmann M.F., Kalinke U., Hengartner H. Neutralizing antiviral antibody responses.
  Advances in Immunology 2001, 79:1-53.
  PubMED

2000

• Ochsenbein A.F., Zinkernagel R.M. Natural antibodies and complement link innate and acquired immunity.
  Immunology Today 2000, 21:624-630.
  PubMED

1999

• Ludewig, B., Odermatt B., Ochsenbein A.F., Zinkernagel R.M., Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases.
  Immunological Reviews 1999, 169:45-54.
  PubMED

Non-Peer Reviewed Articles / Case Reports / Commentaries

• Rothschild S., Betticher D.C., Ochsenbein A.F., Stahel R., Bubendorf L., Gugger M., Brutsche M., Pless M., Gautschi O. Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms.
  Schweizerisches Medizin-Forum 2010, 10:384-388.
• Farese S.A., Ochsenbein A.F. Monokolonale Antikörpertherapie in der Onkologie,
  Schweizerisches Medizin-Forum 2008, 8:160–165
• Ochsenbein A.F. Monoklonale Antikörper als therapeutische Substanzen.
  Schweizerisches Medizin-Forum 2008, 8:140-143
• Cresto N., Barth A., Arnold M., Weimann R., Gschossmann J., Ochsenbein A.F., Kolotas C., Peter H.P., Schiemann U. Extraordinary manifestation of a gastric carcinoma by leptomeningeal carcinomatosis and spinal metastasis.
  Medizinische Klinik 2007, 102:255-258
• Ochsenbein A.F. Schlaglicht Onkologie 2006: Gezielt gegen das Nierenzellkarzinom?,
  Schweizerisches Medizin-Forum 2007, 7:23-24,
• Ochsenbein A.F. Immuntherapien gegen Krebs, Krankheitsabwehr mit Antikörpern, Killerzellen und Co.
  Geriatrie und Praxis Sonderheft DGHO, 2004, 12-17
• Ochsenbein A.F, Fey M.F. Is breast cancer a medical emergency? Commentary.
  Schweizerische Medizinische Wochenschrift 2000, 130:559
• Egger, M., Ochsenbein A.F., Gerber A.U. A young man with sore throat and infection.
  Schweizerische Medizinische Wochenschrift 1997, 127:861-863.
• Imoberdorf, R., Ochsenbein A.F., Ballmer P.E. Acute Phase Reaction.
  Therapie Woche Schweiz 1996, 11:34-38.

Book Chapters

• Surf Med, Guidelines Internal Medicine, 2009, Onkologie